计算溶液所需的质量、体积或浓度。
这是演示店铺,请务下单付款,避免造成你的财物损失。
为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验,建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?),感谢您选择我们!
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
B411998-1mg |
1mg |
现货 ![]() |
| |
B411998-5mg |
5mg |
现货 ![]() |
| |
B411998-10mg |
10mg |
期货 ![]() |
|
别名 | 贝伐珠单抗; 贝伐单抗; Recombinant Bevacizumab Antibody; rhuMab VEGF; Avastin; Anti-Human VEGF; Humanized Antibody; Bevacizumab (Anti-Human VEGF, Humanized Antibody); Bevacizumab; EC 2.7.10.1 antibody; FLT 1 antibody; FLT antibody; Flt-1 antibody; FLT1 antibody; Fm |
---|---|
英文别名 | Recombinant Bevacizumab Antibody; rhuMab VEGF; Avastin; Anti-Human VEGF; Humanized Antibody; Bevacizumab (Anti-Human VEGF, Humanized Antibody); Bevacizumab; EC 2.7.10.1 antibody; FLT 1 antibody; FLT antibody; Flt-1 antibody; FLT1 antibody; Fms like tyrosi |
规格或纯度 | Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated |
英文名称 | Bevacizumab (anti-VEGF) |
稳定性与储存 | Store at -80℃ for 18 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
应用 | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
来源 | CHO supernatant |
储存温度 | -80℃储存,避免反复冻融 |
运输条件 | 超低温冰袋运输 |
产品介绍 |
Bevacizumab 是一种人源化的anti-VEGF单克隆抗体,是VEGF的抑制剂。可与所有人源VEGF-A亚型(和具有生物活性的蛋白水解片段)结合、中和。 Bevacizumab is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments. |
分子量 | 149 kDa(Average) |
---|
PubChem SID | 178103377 |
---|---|
IMGT/mAb-DB | 24 |
Wikipedia | Bevacizumab |
Reactome Reaction | R-HSA-9679477 |
Reactome Drug | R-ALL-9679458 |
输入批号以搜索COA:
Bevacizumab (anti-VEGF) (B411998) - ELISA
Immobilized Recombinant Human VEGF Protein (rp155965) at 1 μg/mL can bind Bevacizumab (anti-VEGF) (B411998) with the EC50 of 4.16 ng/mL.
Bevacizumab (anti-VEGF) (B411998) - SEC
The purity of Bevacizumab (anti-VEGF) (B411998) is more than 95% verified by HPLC.
1. Glade-Bender J, Kandel JJ, Yamashiro DJ. (2003) VEGF blocking therapy in the treatment of cancer.. Expert Opin Biol Ther, 3 (2): (263-76). [PMID:12662141] |
2. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.. N Engl J Med, 349 (5): (427-34). [PMID:12890841] |
3. Tewari KS, Java JJ, Eskander RN, Monk BJ, Burger RA. (2016) Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study.. Ann Oncol, 27 (1): (114-21). [PMID:26487588] |